Literature DB >> 25535238

Metastatic breast cancer presenting as detrusor overactivity.

Aswini Aparna Balachandran1, Jonathan Duckett2.   

Abstract

Breast carcinoma metastatic to the bladder is rare and accounts for approximately 3% of all secondary bladder neoplasms. We examine a case of breast cancer metastatic to the bladder with normal findings at cystoscopy. A 53-year-old woman with a history of breast carcinoma presented with a 6-month history of severe urgency and urgency incontinence. Treatment with multiple antimuscarinic therapies was unsuccessful. Vaginal examination demonstrated a non-mobile uterus with a suggestion of parametrial thickening. Urodynamic studies confirmed detrusor overactivity. CT showed a thickened bladder wall and cystoscopy revealed normal bladder mucosa with reduced bladder capacity. Bladder biopsies identified a poorly differentiated adenocarcinoma with strong oestrogen receptor staining. This was reported as a secondary deposit from a primary breast malignancy. The patient is currently under the care of the breast team and undergoing palliative chemotherapy. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25535238      PMCID: PMC4275719          DOI: 10.1136/bcr-2014-207920

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Secondary malignant tumors of the urinary bladder metastatic from primary foci in distant organs.

Authors:  E J GANEM; J T BATAL
Journal:  J Urol       Date:  1956-06       Impact factor: 7.450

2.  Is cystoscopy indicated for incidentally identified bladder wall thickening?

Authors:  Daniel S McPartlin; Adam P Klausner; Charles U Nottingham; Jeffrey P Wolters; Albert Petrossian; Laura R Carucci; B Mayer Grob
Journal:  Can J Urol       Date:  2013-02       Impact factor: 1.344

3.  Breast carcinoma metastatic to the gallbladder and urinary bladder.

Authors:  F A Herrera; A H Hassanein; B C Cosman; M Bouvet
Journal:  Eur Rev Med Pharmacol Sci       Date:  2010-10       Impact factor: 3.507

4.  Metastatic breast carcinoma to the bladder.

Authors:  J E Pontes; J R Oldford
Journal:  J Urol       Date:  1970-12       Impact factor: 7.450

5.  Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

Authors:  Paul Abrams; Con Kelleher; David Staskin; Tomasz Rechberger; Richard Kay; Reynaldo Martina; Donald Newgreen; Asha Paireddy; Rob van Maanen; Arwin Ridder
Journal:  Eur Urol       Date:  2014-02-19       Impact factor: 20.096

6.  Breast cancer metastatic to the urinary bladder.

Authors:  Jennifer Ramsey; Edwin N Beckman; J Christian Winters
Journal:  Ochsner J       Date:  2008

Review 7.  Metastatic breast cancer to the bladder: a diagnostic challenge and review of the literature.

Authors:  Paul A Feldman; Ralph Madeb; Inna Naroditsky; Sarel Halachmi; Ofer Nativ
Journal:  Urology       Date:  2002-01       Impact factor: 2.649

Review 8.  Urinary complications from breast cancer metastasis: case report and review of the literature.

Authors:  E Vulcano; M Montesano; C Battista; R Carino; G Perrone; B Vincenzi; V Altomare
Journal:  G Chir       Date:  2010-05

9.  Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?

Authors:  Aswini Balachandran; Natasha Curtiss; Maya Basu; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2014-07-17       Impact factor: 2.894

10.  Breast cancer presenting initially with urinary incontinence: a case of bladder metastasis from breast cancer.

Authors:  P S H Soon; W Lynch; P Schwartz
Journal:  Breast       Date:  2004-02       Impact factor: 4.380

  10 in total
  1 in total

1.  Muscarinic cholinergic signaling and overactive bladder-like symptoms associated with invasive bladder cancer.

Authors:  Wei Wei; Minggang Wang; Yunglong Li; Qinggui Meng; Yong Tang; Haoyuan Lu; Wenchao Yu; Qiwei Cheng; You Li; Long Xu; Shaojun Jian; Yuexian Wu; Xianlin Yi; Keji Xie
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.